- Bayer to buy Perfuse Therapeutics for $300M upfrontBayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s firs…Endpoints · 2mo ago↗ source
- Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureA million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion…Endpoints · 2mo ago↗ source
- Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharmaIntercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence…